The PROSPECT II study was published in the March 13th issue of The Lancet, finding that IVUS+NIRS imaging can detect plaques at increased risk for future adverse cardiac outcomes.VIEW ARTICLEVIEW ARTICLE
Together, we are fighting Coronary Artery Disease because the heart is everything.
Infraredx, a Nipro Company, and B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc., Announce Strategic U.S. Collaboration to Execute the IDE Clinical Trial for the SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter.
Now FDA indicated to identify plaque and patients at increased risk of MACE.
Achieve unparalleled insights with the Makoto™ Imaging System and its accompanying Dualpro™ IVUS + NIRS catheter, the only FDA-cleared dual-modality catheter and imaging system indicated for the identification of patients and plaques at increased risk of major adverse cardiac events (MACE).
LRP STUDY RESULTS
See the Makoto™
SYSTEM IN ACTION
NOW AVAILABLE IN THE USA #1 selling Y-Connector in Japan